Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of the ABL kinase inhibitor dasatinib to achieve remission, followed by the bifunctional antibody blinatumomab (which has both anti-CD3 and ant...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 17; pp. 1613 - 1623
Main Authors Foà, Robin, Bassan, Renato, Vitale, Antonella, Elia, Loredana, Piciocchi, Alfonso, Puzzolo, Maria-Cristina, Canichella, Martina, Viero, Piera, Ferrara, Felicetto, Lunghi, Monia, Fabbiano, Francesco, Bonifacio, Massimiliano, Fracchiolla, Nicola, Di Bartolomeo, Paolo, Mancino, Alessandra, De Propris, Maria-Stefania, Vignetti, Marco, Guarini, Anna, Rambaldi, Alessandro, Chiaretti, Sabina
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 22.10.2020
Subjects
Acute lymphoblastic leukemia
Adult
Aged
Aged, 80 and over
Allografts
Antibodies, Bispecific - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone marrow
Cell death
Chemotherapy
Confidence intervals
Consolidation Chemotherapy
Dasatinib - administration & dosage
Design
Female
Gene expression
Glucocorticoids
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Hypotheses
Induction Chemotherapy
Induction therapy
Kinases
Leukemia
Lymphatic leukemia
Lymphocytes
Male
Medical prognosis
Middle Aged
Minimal residual disease
Monoclonal antibodies
Mutation
Pax5 protein
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Protein-tyrosine kinase
Proteins
Remission
Remission Induction
Survival Analysis
Targeted cancer therapy
Transplantation
Treatment Outcome
Online AccessGet full text
ISSN0028-4793
1533-4406
1533-4406
DOI10.1056/NEJMoa2016272

Cover

Abstract In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of the ABL kinase inhibitor dasatinib to achieve remission, followed by the bifunctional antibody blinatumomab (which has both anti-CD3 and anti-CD19 specificity as maintenance therapy), led to complete remission in 98% of the patients.
AbstractList BackgroundOutcomes in patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.MethodsWe conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment.ResultsOf the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1plus]). ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%).ConclusionsA chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.)
Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment. We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment. Of the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an deletion plus additional genetic aberrations ( or , , or both [i.e., ]). mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%). A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).
Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.BACKGROUNDOutcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment.METHODSWe conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment.Of the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1 plus]). ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%).RESULTSOf the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1 plus]). ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%).A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).CONCLUSIONSA chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).
In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of the ABL kinase inhibitor dasatinib to achieve remission, followed by the bifunctional antibody blinatumomab (which has both anti-CD3 and anti-CD19 specificity as maintenance therapy), led to complete remission in 98% of the patients.
Author Bassan, Renato
Guarini, Anna
Lunghi, Monia
Piciocchi, Alfonso
Fracchiolla, Nicola
Vignetti, Marco
Elia, Loredana
Rambaldi, Alessandro
Viero, Piera
De Propris, Maria-Stefania
Foà, Robin
Ferrara, Felicetto
Mancino, Alessandra
Fabbiano, Francesco
Canichella, Martina
Di Bartolomeo, Paolo
Vitale, Antonella
Puzzolo, Maria-Cristina
Bonifacio, Massimiliano
Chiaretti, Sabina
Author_xml – sequence: 1
  givenname: Robin
  surname: Foà
  fullname: Foà, Robin
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 2
  givenname: Renato
  surname: Bassan
  fullname: Bassan, Renato
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 3
  givenname: Antonella
  surname: Vitale
  fullname: Vitale, Antonella
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 4
  givenname: Loredana
  surname: Elia
  fullname: Elia, Loredana
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 5
  givenname: Alfonso
  surname: Piciocchi
  fullname: Piciocchi, Alfonso
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 6
  givenname: Maria-Cristina
  surname: Puzzolo
  fullname: Puzzolo, Maria-Cristina
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 7
  givenname: Martina
  surname: Canichella
  fullname: Canichella, Martina
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 8
  givenname: Piera
  surname: Viero
  fullname: Viero, Piera
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 9
  givenname: Felicetto
  surname: Ferrara
  fullname: Ferrara, Felicetto
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 10
  givenname: Monia
  surname: Lunghi
  fullname: Lunghi, Monia
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 11
  givenname: Francesco
  surname: Fabbiano
  fullname: Fabbiano, Francesco
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 12
  givenname: Massimiliano
  surname: Bonifacio
  fullname: Bonifacio, Massimiliano
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 13
  givenname: Nicola
  surname: Fracchiolla
  fullname: Fracchiolla, Nicola
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 14
  givenname: Paolo
  surname: Di Bartolomeo
  fullname: Di Bartolomeo, Paolo
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 15
  givenname: Alessandra
  surname: Mancino
  fullname: Mancino, Alessandra
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 16
  givenname: Maria-Stefania
  surname: De Propris
  fullname: De Propris, Maria-Stefania
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 17
  givenname: Marco
  surname: Vignetti
  fullname: Vignetti, Marco
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 18
  givenname: Anna
  surname: Guarini
  fullname: Guarini, Anna
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 19
  givenname: Alessandro
  surname: Rambaldi
  fullname: Rambaldi, Alessandro
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
– sequence: 20
  givenname: Sabina
  surname: Chiaretti
  fullname: Chiaretti, Sabina
  organization: From the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome (R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., M.V., S.C.), Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Data Center, Fondazione GIMEMA Franco Mandelli Onlus (A.P., M.V.), and the Department of Molecular Medicine, Sapienza University of Rome (A.G.), Rome, the Hematology Unit, Ospedale dell’Angelo and Ospedale SS Giovanni e Paolo, Venice (R.B., P.V., A.M.), the Division of Hematology, Cardarelli Hospital, Naples (F. Ferrara), the Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara (M.L.), Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia Cervello, Palermo (F. Fabbiano), the Department of Medicine, Section of Hematology, University of Verona, Verona (M.B.), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano (N.F.), and the Department of Oncology–Hematology, University of Milan (A.R.), Milan, the Department of Hematology, Ospedale Civile, Pescara (P.D.B.), and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (A.R.) — all in Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33085860$$D View this record in MEDLINE/PubMed
BookMark eNp10TtPwzAQB3ALFUFbGFlRJITEErDjvDyW8lZ5DDBbZ8cVLrFdYgepG9-Bb8gnIVAYqNRbbvnd6fS_AepZZxVCewQfE5zlJ3fnN7cOEkzypEg2UJ9klMZpivMe6mOclHFaMLqNBt7PcFckZVtom1JcZmWO--j-DDwEbbX4fP84rbWF0BpnQERT10QPz_GD8zroNxWNZBtUNFmY-bMTNfigZTRR7YsyGiJto1HV1sHvoM0p1F7t_vYhero4fxxfxZP7y-vxaBJLynCIWcYIS4RkCS7TijLIMJWUSCEoECFLRaEqpCwYUYCrrBBAKklzIDIv2BQKOkRHy73zxr22ygdutJeqrsEq13qepBnNyzzFrKMHK3Tm2sZ21_0o0gVBv9X-r2qFURWfN9pAs-B_UXWALoFsnPeNmnKpQxeds6EBXXOC-fdD-L-HdFPxytTf4nX-cOmN8dyqmVnjvgAORpeA
CitedBy_id crossref_primary_10_3324_haematol_2023_283815
crossref_primary_10_1016_j_beha_2022_101404
crossref_primary_10_3390_ijms231911836
crossref_primary_10_1182_blood_2023021752
crossref_primary_10_1038_s41572_024_00525_x
crossref_primary_10_1038_s41408_022_00621_9
crossref_primary_10_1111_bjh_19104
crossref_primary_10_1182_blood_2022016194
crossref_primary_10_1016_j_beha_2023_101485
crossref_primary_10_1080_10428194_2022_2090555
crossref_primary_10_1080_2162402X_2022_2077898
crossref_primary_10_1016_S2152_2650_24_00351_3
crossref_primary_10_1016_j_leukres_2021_106647
crossref_primary_10_1007_s11899_023_00718_3
crossref_primary_10_1097_HS9_0000000000000726
crossref_primary_10_3390_ijms22126411
crossref_primary_10_1080_10428194_2023_2235450
crossref_primary_10_1016_j_medcli_2022_01_007
crossref_primary_10_1007_s13691_024_00725_y
crossref_primary_10_1080_16078454_2024_2439605
crossref_primary_10_1200_JCO_23_01392
crossref_primary_10_6004_jnccn_2021_0042
crossref_primary_10_1002_ajh_26238
crossref_primary_10_1007_s00277_023_05519_5
crossref_primary_10_3390_cancers14030565
crossref_primary_10_1007_s00277_021_04699_2
crossref_primary_10_1136_jitc_2022_006619
crossref_primary_10_1007_s11899_024_00736_9
crossref_primary_10_1182_blood_2022017035
crossref_primary_10_1016_j_bulcan_2021_10_003
crossref_primary_10_1016_S2352_3026_22_00294_0
crossref_primary_10_1136_jitc_2021_003766
crossref_primary_10_3390_cells14050371
crossref_primary_10_1002_cam4_70161
crossref_primary_10_1002_cncr_34667
crossref_primary_10_3390_hematolrep15040068
crossref_primary_10_1056_NEJMc2033785
crossref_primary_10_3389_fonc_2021_804714
crossref_primary_10_1080_14728214_2021_1956462
crossref_primary_10_1186_s40164_020_00189_9
crossref_primary_10_1038_s41467_023_42565_z
crossref_primary_10_1080_14712598_2024_2384086
crossref_primary_10_1007_s12288_025_01988_y
crossref_primary_10_1111_bjh_19682
crossref_primary_10_1182_bloodadvances_2022008216
crossref_primary_10_1016_j_lanwpc_2023_100818
crossref_primary_10_1007_s00277_024_05816_7
crossref_primary_10_1016_j_retram_2023_103392
crossref_primary_10_1126_sciadv_adq4274
crossref_primary_10_1017_pcm_2023_9
crossref_primary_10_1097_CCO_0000000000001086
crossref_primary_10_3390_ijms23084442
crossref_primary_10_1016_j_clml_2024_02_017
crossref_primary_10_1038_s41375_023_01822_2
crossref_primary_10_3390_cancers15102812
crossref_primary_10_1177_20406207231151294
crossref_primary_10_3390_cancers15164137
crossref_primary_10_1016_j_drup_2024_101082
crossref_primary_10_1182_hematology_2022000413
crossref_primary_10_3324_haematol_2022_281229
crossref_primary_10_1007_s11899_021_00648_y
crossref_primary_10_1002_hem3_122
crossref_primary_10_1200_JCO_24_00272
crossref_primary_10_1016_S2152_2650_22_00656_5
crossref_primary_10_3390_v17010133
crossref_primary_10_1182_blood_2023021501
crossref_primary_10_1002_jha2_677
crossref_primary_10_3390_cancers15041349
crossref_primary_10_1016_j_clml_2021_12_005
crossref_primary_10_1016_j_heliyon_2024_e27358
crossref_primary_10_1002_iid3_1087
crossref_primary_10_1016_S2152_2650_21_01221_0
crossref_primary_10_1016_j_heliyon_2023_e23929
crossref_primary_10_1038_s43018_024_00863_5
crossref_primary_10_1016_S2352_3026_23_00088_1
crossref_primary_10_1016_j_clml_2024_06_002
crossref_primary_10_7759_cureus_54154
crossref_primary_10_3390_cancers17050779
crossref_primary_10_3390_cancers14246211
crossref_primary_10_3390_children11111329
crossref_primary_10_1182_bloodadvances_2021004813
crossref_primary_10_1002_ajh_27378
crossref_primary_10_1080_10428194_2024_2387728
crossref_primary_10_1080_10428194_2024_2426052
crossref_primary_10_1002_hem3_82
crossref_primary_10_1007_s11899_023_00691_x
crossref_primary_10_1007_s44228_022_00006_6
crossref_primary_10_3390_cancers15020374
crossref_primary_10_1016_S2352_3026_23_00095_9
crossref_primary_10_1080_14737140_2022_2093718
crossref_primary_10_1016_j_beha_2021_101319
crossref_primary_10_2298_MPNS22S1015S
crossref_primary_10_1038_s41392_023_01521_5
crossref_primary_10_1200_JCO_23_01075
crossref_primary_10_1016_S2152_2650_22_00657_7
crossref_primary_10_3238_PersASCO_2021_07_02_12
crossref_primary_10_3390_cancers14071805
crossref_primary_10_3390_onco2040016
crossref_primary_10_1200_EDBK_349647
crossref_primary_10_1177_1060028020988411
crossref_primary_10_1186_s13256_021_02771_z
crossref_primary_10_3389_fonc_2023_1237031
crossref_primary_10_1016_j_ejcped_2025_100214
crossref_primary_10_1097_HS9_0000000000000899
crossref_primary_10_3324_haematol_2020_270645
crossref_primary_10_1002_cncr_33933
crossref_primary_10_1038_s41571_020_00451_3
crossref_primary_10_1001_jamaoncol_2022_2398
crossref_primary_10_1080_17474086_2022_2125375
crossref_primary_10_1182_blood_2021011822
crossref_primary_10_1002_ajh_27475
crossref_primary_10_1053_j_semdp_2023_04_003
crossref_primary_10_1002_hon_3136
crossref_primary_10_1126_sciadv_add6403
crossref_primary_10_1038_s41375_021_01455_3
crossref_primary_10_20515_otd_1518969
crossref_primary_10_3324_haematol_2021_280289
crossref_primary_10_1016_j_mam_2023_101190
crossref_primary_10_1371_journal_pone_0253896
crossref_primary_10_1038_s43018_023_00586_z
crossref_primary_10_1002_ajh_27237
crossref_primary_10_3324_haematol_2021_279177
crossref_primary_10_3390_jcm11195594
crossref_primary_10_1002_ajh_26949
crossref_primary_10_1016_j_leukres_2021_106666
crossref_primary_10_1002_mco2_124
crossref_primary_10_1016_S2352_3026_22_00036_9
crossref_primary_10_3389_fonc_2021_677034
crossref_primary_10_1136_jitc_2023_008518
crossref_primary_10_3390_jcm10091926
crossref_primary_10_1080_10428194_2022_2136949
crossref_primary_10_1186_s40164_022_00265_2
crossref_primary_10_2147_BTT_S290294
crossref_primary_10_1016_j_ejps_2023_106647
crossref_primary_10_1002_ajh_26813
crossref_primary_10_1007_s10637_024_01435_1
crossref_primary_10_1111_ejh_14405
crossref_primary_10_1182_blood_2023023568
crossref_primary_10_1016_j_beha_2021_101331
crossref_primary_10_1200_JCO_21_01766
crossref_primary_10_1111_ejh_14089
crossref_primary_10_1002_ajh_26816
crossref_primary_10_1016_S2352_3026_22_00293_9
crossref_primary_10_1038_s41392_021_00868_x
crossref_primary_10_1182_blood_2022015956
crossref_primary_10_1016_j_leukres_2022_107004
crossref_primary_10_1080_10428194_2023_2232496
crossref_primary_10_1007_s00277_023_05162_0
crossref_primary_10_1080_10428194_2023_2189803
crossref_primary_10_1007_s11912_021_01086_y
crossref_primary_10_1182_blood_2024025800
crossref_primary_10_1111_bjh_18537
crossref_primary_10_3389_fonc_2024_1324859
crossref_primary_10_1016_j_critrevonc_2024_104317
crossref_primary_10_1186_s13045_021_01077_3
crossref_primary_10_3389_fcvm_2021_758010
crossref_primary_10_1007_s12325_023_02497_y
crossref_primary_10_3324_haematol_2020_260935
crossref_primary_10_1038_s41571_024_00905_y
crossref_primary_10_1016_S2152_2650_21_01226_X
crossref_primary_10_1007_s11899_023_00714_7
crossref_primary_10_1007_s00277_022_04796_w
crossref_primary_10_1007_s12185_025_03917_1
crossref_primary_10_1080_10428194_2022_2032035
crossref_primary_10_1002_ccr3_9512
crossref_primary_10_1016_j_intimp_2022_109636
crossref_primary_10_1016_j_jaccao_2022_07_014
crossref_primary_10_3324_haematol_2021_280395
crossref_primary_10_1016_j_apsb_2024_03_027
crossref_primary_10_1182_bloodadvances_2021004607
crossref_primary_10_3390_cancers15245783
crossref_primary_10_1080_10428194_2021_1964022
crossref_primary_10_2147_CMAR_S379807
crossref_primary_10_1002_ajh_27041
crossref_primary_10_1007_s10238_023_01000_9
crossref_primary_10_1002_ajh_26634
crossref_primary_10_1016_j_therap_2021_12_003
crossref_primary_10_1002_hon_2913
crossref_primary_10_1182_blood_2022017793
crossref_primary_10_3390_cimb47020129
crossref_primary_10_1002_ajh_26993
crossref_primary_10_3390_genes12091355
crossref_primary_10_46989_001c_117026
crossref_primary_10_3324_haematol_2020_247973
crossref_primary_10_7889_tct_21_019
crossref_primary_10_1111_ejh_13972
crossref_primary_10_3390_cancers15184623
crossref_primary_10_1016_j_modpat_2024_100466
crossref_primary_10_1016_j_clml_2021_09_011
crossref_primary_10_3390_cancers14194554
crossref_primary_10_1056_NEJMe2027937
crossref_primary_10_1007_s00761_022_01165_0
crossref_primary_10_1016_j_clml_2022_12_011
crossref_primary_10_1016_j_annonc_2023_09_3112
crossref_primary_10_1016_S2352_3026_24_00285_0
crossref_primary_10_1016_j_clml_2021_06_022
crossref_primary_10_1080_14712598_2023_2166786
crossref_primary_10_1016_j_ymthe_2024_05_039
crossref_primary_10_1016_S1636_5410_23_48737_5
crossref_primary_10_1073_pnas_2423169122
crossref_primary_10_1016_S0140_6736_23_00521_4
crossref_primary_10_1002_ajh_26622
crossref_primary_10_1007_s00761_022_01166_z
crossref_primary_10_1007_s11864_021_00925_1
crossref_primary_10_1182_bloodadvances_2022007764
crossref_primary_10_1186_s13045_023_01409_5
crossref_primary_10_3390_jcm10173792
crossref_primary_10_3390_cancers13020295
crossref_primary_10_3390_cancers14174290
crossref_primary_10_1007_s11912_021_01111_0
crossref_primary_10_1080_2162402X_2022_2083479
crossref_primary_10_1002_ajh_26175
crossref_primary_10_2139_ssrn_4094834
crossref_primary_10_1155_2024_4751168
crossref_primary_10_1016_j_blre_2024_101251
crossref_primary_10_1016_S2352_3026_22_00351_9
crossref_primary_10_1080_10428194_2023_2206181
crossref_primary_10_1080_16078454_2022_2150386
crossref_primary_10_1182_bloodadvances_2021004821
crossref_primary_10_1182_bloodadvances_2022009279
crossref_primary_10_1182_hem_V22_1_2025210
crossref_primary_10_1002_cam4_7062
crossref_primary_10_1016_j_clml_2022_03_001
crossref_primary_10_1056_NEJMra2113347
crossref_primary_10_3389_fonc_2024_1491099
crossref_primary_10_1038_s41375_021_01496_8
crossref_primary_10_1007_s00432_022_04039_5
crossref_primary_10_1016_S2152_2650_22_00653_X
crossref_primary_10_1111_bjh_18975
crossref_primary_10_3390_cancers15133346
crossref_primary_10_1016_S2352_3026_22_00054_0
crossref_primary_10_1200_JCO_24_00108
crossref_primary_10_1080_10428194_2024_2402808
crossref_primary_10_1016_j_ejcped_2024_100200
crossref_primary_10_1182_hematology_2024000531
crossref_primary_10_7759_cureus_73988
crossref_primary_10_1007_s00277_021_04587_9
crossref_primary_10_1016_j_jtct_2022_12_018
crossref_primary_10_1080_10428194_2024_2396046
crossref_primary_10_1200_GO_22_00292
crossref_primary_10_1016_j_clml_2021_08_003
crossref_primary_10_1080_14656566_2021_1931683
crossref_primary_10_1111_jcpt_13741
crossref_primary_10_1182_hematology_2024000532
crossref_primary_10_1080_10428194_2024_2364043
crossref_primary_10_1177_20406207231154713
crossref_primary_10_3390_ijms24054661
crossref_primary_10_1038_s41409_021_01279_w
crossref_primary_10_1038_s41375_021_01277_3
crossref_primary_10_1007_s11912_022_01220_4
crossref_primary_10_1111_bjh_17879
crossref_primary_10_1200_JCO_23_01351
crossref_primary_10_1016_j_clml_2023_01_013
crossref_primary_10_3324_haematol_2021_280578
crossref_primary_10_1016_S2152_2650_23_00286_0
crossref_primary_10_1182_hematology_2022000357
crossref_primary_10_3390_genes12050687
crossref_primary_10_1016_j_trecan_2024_06_001
crossref_primary_10_1093_stcltm_szac066
crossref_primary_10_1038_s41409_022_01796_2
crossref_primary_10_1182_blood_2023023502
crossref_primary_10_3390_cells10061421
crossref_primary_10_1002_cncr_33539
crossref_primary_10_1016_S2352_3026_22_00285_X
crossref_primary_10_3390_cancers17010104
crossref_primary_10_1038_s41408_022_00766_7
crossref_primary_10_3390_jcm11226761
crossref_primary_10_1016_S2352_3026_23_00064_9
crossref_primary_10_3390_ijms231810957
crossref_primary_10_1182_hem_V19_6_202267
crossref_primary_10_1038_s43018_024_00778_1
crossref_primary_10_3390_cancers15184550
crossref_primary_10_1016_j_clml_2023_12_013
crossref_primary_10_1182_blood_2020010322
crossref_primary_10_1182_blood_2023023153
crossref_primary_10_1111_bjh_17622
crossref_primary_10_3390_cancers16071288
crossref_primary_10_7759_cureus_32467
crossref_primary_10_1016_S2152_2650_24_00354_9
crossref_primary_10_5045_br_2022_2020305
crossref_primary_10_1016_j_leukres_2024_107438
crossref_primary_10_3748_wjg_v29_i33_4942
crossref_primary_10_2147_CMAR_S353022
crossref_primary_10_3390_cancers15092411
crossref_primary_10_1080_16078454_2024_2335856
crossref_primary_10_2217_fon_2020_1220
crossref_primary_10_3390_cells10071697
crossref_primary_10_1038_s41409_022_01691_w
crossref_primary_10_1182_blood_2023023152
crossref_primary_10_1080_17474086_2024_2357273
crossref_primary_10_1182_hematology_2022000338
crossref_primary_10_3324_haematol_2020_278077
crossref_primary_10_1002_pbc_28924
crossref_primary_10_1038_s41419_023_06019_0
crossref_primary_10_1182_bloodadvances_2022009072
crossref_primary_10_3389_fonc_2022_981036
crossref_primary_10_1182_hematology_2021000226
crossref_primary_10_3390_jpm11080715
crossref_primary_10_1002_ajh_26537
crossref_primary_10_1002_jha2_1064
crossref_primary_10_1016_S2152_2650_22_00654_1
crossref_primary_10_1038_s41409_022_01797_1
crossref_primary_10_1186_s13045_021_01084_4
crossref_primary_10_3390_jcm14062055
crossref_primary_10_1016_S2152_2650_21_01208_8
crossref_primary_10_3390_ijms242316899
crossref_primary_10_1016_j_yao_2023_01_018
crossref_primary_10_1080_10428194_2025_2449582
crossref_primary_10_1080_13543784_2021_1928074
crossref_primary_10_24884_1607_4181_2023_30_2_30_39
crossref_primary_10_1016_S2352_3026_22_00319_2
crossref_primary_10_1016_j_medcle_2022_04_006
crossref_primary_10_1080_17474086_2022_2077187
crossref_primary_10_3389_fimmu_2023_1181620
crossref_primary_10_1016_j_clml_2023_06_007
crossref_primary_10_1089_jayao_2021_0200
crossref_primary_10_1016_j_hpr_2022_300688
Cites_doi 10.1182/blood.V130.Suppl_1.99.99
10.1038/sj.leu.2404586
10.1182/blood-2017-07-796862
10.1182/bloodadvances.2016001495
10.1200/JCO.2010.28.1287
10.3324/haematol.2016.144535
10.1016/j.bbmt.2016.06.022
10.1016/j.jbi.2008.08.010
10.1182/blood-2006-10-052746
10.1182/blood-2005-11-4386
10.1111/j.1365-2141.2009.07666.x
10.1038/leu.2016.174
10.1182/blood-2009-12-261586
10.1038/s41375-019-0413-0
10.1182/blood.V126.23.81.81
10.1016/j.jbi.2019.103208
10.1093/annonc/mdw123
10.1200/JCO.2005.03.2177
10.1182/blood-2015-03-636548
10.3324/haematol.2018.196055
10.1182/blood-2016-02-700153
10.1182/blood-2011-05-351403
10.1182/blood-2013-09-529008
10.1016/S1470-2045(15)00207-7
10.1038/leu.2017.41
10.1056/NEJMoa0808253
10.1182/blood.V124.21.2289.2289
10.3324/haematol.2009.011221
10.3947/ic.2018.50.2.153
10.1016/j.bbmt.2012.08.021
10.1182/blood-2017-08-798322
10.1038/sj.leu.2404320
10.1182/blood-2006-03-011908
10.1111/j.1365-2141.2012.09182.x
ContentType Journal Article
Contributor Sica, Simona
Borlenghi, Erika
Ciceri, Fabio
Di Raimondo, Francesco
Gaidano, Gianluca
Cambrin, Giovanna Rege
Venditti, Adriano
Martino, Bruno
Bonifacio, Massimiliano
Di Bartolomeo, Nicola
Della Porta, Matteo
Bassan, Renato
Fracchiolla, Nicola
Di Renzo, Nicola
Cudillo, Laura
Falini, Brunangelo
Crugnola, Monica
Rambaldi, Alessandro
Cignetti, Alessandro
Bosi, Alberto
Albano, Francesco
Foà, Robin
Ferrara, Felicetto
Califano, Catello
Rondoni, Michela
Fabbiano, Francesco
Chiaretti, Sabina
Contributor_xml – sequence: 1
  givenname: Renato
  surname: Bassan
  fullname: Bassan, Renato
– sequence: 2
  givenname: Felicetto
  surname: Ferrara
  fullname: Ferrara, Felicetto
– sequence: 3
  givenname: Robin
  surname: Foà
  fullname: Foà, Robin
– sequence: 4
  givenname: Sabina
  surname: Chiaretti
  fullname: Chiaretti, Sabina
– sequence: 5
  givenname: Alessandro
  surname: Rambaldi
  fullname: Rambaldi, Alessandro
– sequence: 6
  givenname: Gianluca
  surname: Gaidano
  fullname: Gaidano, Gianluca
– sequence: 7
  givenname: Francesco
  surname: Fabbiano
  fullname: Fabbiano, Francesco
– sequence: 8
  givenname: Nicola
  surname: Di Bartolomeo
  fullname: Di Bartolomeo, Nicola
– sequence: 9
  givenname: Massimiliano
  surname: Bonifacio
  fullname: Bonifacio, Massimiliano
– sequence: 10
  givenname: Nicola
  surname: Fracchiolla
  fullname: Fracchiolla, Nicola
– sequence: 11
  givenname: Francesco
  surname: Albano
  fullname: Albano, Francesco
– sequence: 12
  givenname: Brunangelo
  surname: Falini
  fullname: Falini, Brunangelo
– sequence: 13
  givenname: Giovanna Rege
  surname: Cambrin
  fullname: Cambrin, Giovanna Rege
– sequence: 14
  givenname: Nicola
  surname: Di Renzo
  fullname: Di Renzo, Nicola
– sequence: 15
  givenname: Alessandro
  surname: Cignetti
  fullname: Cignetti, Alessandro
– sequence: 16
  givenname: Francesco
  surname: Di Raimondo
  fullname: Di Raimondo, Francesco
– sequence: 17
  givenname: Alberto
  surname: Bosi
  fullname: Bosi, Alberto
– sequence: 18
  givenname: Bruno
  surname: Martino
  fullname: Martino, Bruno
– sequence: 19
  givenname: Simona
  surname: Sica
  fullname: Sica, Simona
– sequence: 20
  givenname: Monica
  surname: Crugnola
  fullname: Crugnola, Monica
– sequence: 21
  givenname: Fabio
  surname: Ciceri
  fullname: Ciceri, Fabio
– sequence: 22
  givenname: Erika
  surname: Borlenghi
  fullname: Borlenghi, Erika
– sequence: 23
  givenname: Michela
  surname: Rondoni
  fullname: Rondoni, Michela
– sequence: 24
  givenname: Matteo
  surname: Della Porta
  fullname: Della Porta, Matteo
– sequence: 25
  givenname: Catello
  surname: Califano
  fullname: Califano, Catello
– sequence: 26
  givenname: Laura
  surname: Cudillo
  fullname: Cudillo, Laura
– sequence: 27
  givenname: Adriano
  surname: Venditti
  fullname: Venditti, Adriano
Copyright Copyright © 2020 Massachusetts Medical Society. All rights reserved.
Copyright © 2020 Massachusetts Medical Society.
Copyright_xml – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved.
– notice: Copyright © 2020 Massachusetts Medical Society.
CorporateAuthor GIMEMA Investigators
CorporateAuthor_xml – name: GIMEMA Investigators
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7RV
7X7
7XB
8AO
8C1
8FE
8FH
8FI
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K0Y
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1056/NEJMoa2016272
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials - QC
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
New England Journal of Medicine
ProQuest Biological Science Collection
Consumer Health Database
Healthcare Administration Database
Medical Database
Psychology Database
Research Library
Science Database
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
elibrary
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
New England Journal of Medicine
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList ProQuest One Psychology
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-4406
EndPage 1623
ExternalDocumentID 33085860
10_1056_NEJMoa2016272
NJ202010223831708
Genre Original Article
Research Support, Non-U.S. Gov't
Clinical Trial, Phase II
Journal Article
GroupedDBID -
0R
0WA
123
186
1VV
29N
2KS
2WC
34G
39C
4
4.4
53G
55
5RE
7FN
7RV
7X7
85S
8AO
8C1
8FE
8FH
8FI
AACLI
AAEJM
AAIKC
AALRV
AAPBV
AAQQT
AARDX
AAWTL
ABACO
ABEHJ
ABFLS
ABIVO
ABOCM
ABPPZ
ABPTK
ABQIJ
ABUWG
ABWJO
ACGFS
ACGOD
ACJLH
ACNCT
ACPRK
ACRZS
ADBBV
ADBIT
ADCBC
AENEX
AETEA
AFFNX
AFHKK
AFKRA
AGFXO
AGNAY
AHMBA
AJJEV
AJVPN
ALMA_UNASSIGNED_HOLDINGS
AN0
AQUVI
AZQEC
BBAFP
BBNVY
BCU
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BVXVI
C45
CJ0
CO
CS3
DCD
DU5
DWQXO
DZ
EBS
ET
EX3
F5P
FD8
FM.
FYUFA
GJ
GNUQQ
GUQSH
HCIFZ
HZ
I4R
IH2
K-O
KM
KOO
L7B
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MVM
N9A
NAPCQ
NEJ
O9-
OK1
OMK
OVD
P-O
P-S
P2P
PADUT
PCD
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
QJJ
RHI
RWL
RXW
S10
S6N
SJFOW
SJN
TAE
TAF
TEORI
TN5
TUQ
TWZ
UCV
UKR
UMD
VQA
W2G
WH7
WOQ
WOW
X
X7M
XJT
XYN
XZL
YCJ
YNT
YRY
YZZ
ZA5
ZHY
ZR0
---
-DZ
-ET
-~X
.-4
.55
.CO
.GJ
0R~
36B
AAMNW
AAYXX
ABBLC
ABCQX
ABDQB
ABJNI
ACKOT
ACPFK
ADRHT
ADUKH
AERZD
AFOSN
AGHSJ
ALIPV
BYPQX
CCPQU
CITATION
H13
HF~
HMCUK
HZ~
N4W
PHGZM
PHGZT
PSYQQ
UKHRP
YFH
YR2
YR5
YYP
ZCA
ZVN
~KM
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
BEC
K0Y
MBDVC
PKEHL
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c390t-959192bc92084d39a503c31cbb3a1bc8e3ad7cc791ea0d57ba1dc36a1c679fa73
IEDL.DBID 8C1
ISSN 0028-4793
1533-4406
IngestDate Fri Sep 05 06:37:34 EDT 2025
Sat Aug 23 13:41:13 EDT 2025
Mon Jul 21 05:48:55 EDT 2025
Thu Apr 24 23:01:22 EDT 2025
Tue Jul 01 01:43:31 EDT 2025
Tue Dec 21 14:38:59 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 17
Language English
License Copyright © 2020 Massachusetts Medical Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c390t-959192bc92084d39a503c31cbb3a1bc8e3ad7cc791ea0d57ba1dc36a1c679fa73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ORCID 0000-0003-0716-1686
OpenAccessLink https://www.nejm.org/doi/pdf/10.1056/NEJMoa2016272?articleTools=true
PMID 33085860
PQID 2453158639
PQPubID 40644
PageCount 11
ParticipantIDs proquest_miscellaneous_2453686409
proquest_journals_2453158639
pubmed_primary_33085860
crossref_citationtrail_10_1056_NEJMoa2016272
crossref_primary_10_1056_NEJMoa2016272
mms_nejm_10_1056_NEJMoa2016272
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20201022
2020-10-22
PublicationDateYYYYMMDD 2020-10-22
PublicationDate_xml – month: 10
  year: 2020
  text: 20201022
  day: 22
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Boston
PublicationTitle The New England journal of medicine
PublicationTitleAlternate N Engl J Med
PublicationYear 2020
Publisher Massachusetts Medical Society
Publisher_xml – name: Massachusetts Medical Society
References Chiaretti, S, Vitale, A, Elia, L (r019) 2015; 126
Pfeifer, H, Cazzaniga, G, van der Velden, VHJ (r023) 2019; 33
Fielding, AK, Rowe, JM, Buck, G (r011) 2014; 123
Pfeifer, H, Raum, K, Markovic, S (r035) 2018; 131
Aldoss, I, Gaal, K, Al Malki, MM (r031) 2016; 22
de Labarthe, A, Rousselot, P, Huguet-Rigal, F (r004) 2007; 109
Fedullo, AL, Messina, M, Elia, L (r024) 2019; 104
Jabbour, E, Kantarjian, H, Ravandi, F (r033) 2015; 16
Thyagu, S, Minden, MD, Gupta, V (r009) 2012; 158
Vignetti, M, Fazi, P, Cimino, G (r016) 2007; 109
Chiaretti, S, Vitale, A, Piciocchi, A (r018) 2016; 101
Duell, J, Dittrich, M, Bedke, T (r026) 2017; 31
Bassan, R, Rossi, G, Pogliani, EM (r007) 2010; 28
Choi, JK, Cho, SY, Choi, SM (r029) 2018; 50
Delannoy, A, Delabesse, E, Lhéritier, V (r002) 2006; 20
Ravandi, F, Othus, M, O’Brien, SM (r015) 2016; 1
Yoon, JH, Yhim, HY, Kwak, JY (r013) 2016; 27
Mullighan, CG, Su, X, Zhang, J (r025) 2009; 360
Gruber, F, Mustjoki, S, Porkka, K (r005) 2009; 145
Elia, L, Mancini, M, Moleti, L (r021) 2003; 88
Gökbuget, N, Dombret, H, Bonifacio, M (r020) 2018; 131
Kim, D-Y, Joo, Y-D, Lim, S-N (r012) 2015; 126
Jabbour, E, Kantarjian, HM, Deborah, A (r032) 2014; 124
Ribera, J-M, Oriol, A, González, M (r006) 2010; 95
Rousselot, P, Coudé, MM, Gokbuget, N (r014) 2016; 128
Harris, PA, Taylor, R, Thielke, R, Payne, J, Gonzalez, N, Conde, JG (r027) 2009; 42
Harris, PA, Taylor, R, Minor, BL (r028) 2019; 95
Martinelli, G, Piciocchi, A, Papayannidis, C (r034) 2017; 130
Ravandi, F, O’Brien, S, Thomas, D (r008) 2010; 116
Yanada, M, Takeuchi, J, Sugiura, I (r003) 2006; 24
Tanguy-Schmidt, A, Rousselot, P, Chalandon, Y (r010) 2013; 19
Foà, R, Vitale, A, Vignetti, M (r017) 2011; 118
Ishiyama, K, Kitawaki, T, Sugimoto, N (r030) 2017; 31
van der Velden, VHJ, Cazzaniga, G, Schrauder, A (r022) 2007; 21
Wassmann, B, Pfeifer, H, Goekbuget, N (r001) 2006; 108
Elia L (e_1_3_5_22_2) 2003; 88
e_1_3_5_28_2
e_1_3_5_27_2
e_1_3_5_26_2
e_1_3_5_25_2
e_1_3_5_24_2
e_1_3_5_23_2
e_1_3_5_21_2
e_1_3_5_29_2
e_1_3_5_2_2
e_1_3_5_8_2
e_1_3_5_20_2
e_1_3_5_7_2
e_1_3_5_9_2
e_1_3_5_4_2
e_1_3_5_3_2
e_1_3_5_6_2
e_1_3_5_5_2
e_1_3_5_17_2
e_1_3_5_16_2
e_1_3_5_15_2
e_1_3_5_14_2
e_1_3_5_36_2
e_1_3_5_12_2
e_1_3_5_35_2
e_1_3_5_13_2
e_1_3_5_34_2
e_1_3_5_10_2
e_1_3_5_33_2
e_1_3_5_11_2
e_1_3_5_32_2
e_1_3_5_19_2
e_1_3_5_18_2
e_1_3_5_31_2
e_1_3_5_30_2
33169006 - Nat Rev Clin Oncol. 2021 Jan;18(1):6
33085866 - N Engl J Med. 2020 Oct 22;383(17):1673-1674
33503351 - N Engl J Med. 2021 Jan 28;384(4):384
References_xml – volume: 21
  start-page: 604
  year: 2007
  end-page: 611
  ident: r022
  article-title: Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
  publication-title: Leukemia
– volume: 31
  start-page: 2181
  year: 2017
  end-page: 2190
  ident: r026
  article-title: Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
  publication-title: Leukemia
– volume: 28
  start-page: 3644
  year: 2010
  end-page: 3652
  ident: r007
  article-title: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
  publication-title: J Clin Oncol
– volume: 130
  start-page: 99
  year: 2017
  end-page: 99
  ident: r034
  article-title: First report of the GIMEMA LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  publication-title: Blood
– volume: 116
  start-page: 2070
  year: 2010
  end-page: 2077
  ident: r008
  article-title: First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
  publication-title: Blood
– volume: 33
  start-page: 1910
  year: 2019
  end-page: 1922
  ident: r023
  article-title: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
  publication-title: Leukemia
– volume: 31
  start-page: 203
  year: 2017
  end-page: 212
  ident: r030
  article-title: Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph leukemia patients treated with dasatinib.
  publication-title: Leukemia
– volume: 108
  start-page: 1469
  year: 2006
  end-page: 1477
  ident: r001
  article-title: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  publication-title: Blood
– volume: 95
  start-page: 87
  year: 2010
  end-page: 95
  ident: r006
  article-title: Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of the CSTIBES02 trial.
  publication-title: Haematologica
– volume: 131
  start-page: 1464
  year: 2018
  end-page: 1475
  ident: r035
  article-title: Genomic CDKN2A/2B deletions in adult Ph ALL are adverse despite allogeneic stem cell transplantation.
  publication-title: Blood
– volume: 126
  start-page: 81
  year: 2015
  end-page: 81
  ident: r019
  article-title: Multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients: updated results and refined genetic-based prognostic stratification.
  publication-title: Blood
– volume: 131
  start-page: 1522
  year: 2018
  end-page: 1531
  ident: r020
  article-title: Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
  publication-title: Blood
– volume: 95
  start-page: 103208
  year: 2019
  end-page: 103208
  ident: r028
  article-title: The REDCap consortium: building an international community of software platform partners.
  publication-title: J Biomed Inform
– volume: 42
  start-page: 377
  year: 2009
  end-page: 381
  ident: r027
  article-title: Research Electronic Data Capture (REDCap) — a metadata-driven methodology and workflow process for providing translational research informatics support.
  publication-title: J Biomed Inform
– volume: 20
  start-page: 1526
  year: 2006
  end-page: 1532
  ident: r002
  article-title: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
  publication-title: Leukemia
– volume: 360
  start-page: 470
  year: 2009
  end-page: 480
  ident: r025
  article-title: Deletion of and prognosis in acute lymphoblastic leukemia.
  publication-title: N Engl J Med
– volume: 19
  start-page: 150
  year: 2013
  end-page: 155
  ident: r010
  article-title: Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
  publication-title: Biol Blood Marrow Transplant
– volume: 50
  start-page: 153
  year: 2018
  end-page: 159
  ident: r029
  article-title: Cytomegalovirus colitis during dasatinib treatment for patients with hematologic malignancy: case series and literature review.
  publication-title: Infect Chemother
– volume: 22
  start-page: 1900
  year: 2016
  end-page: 1903
  ident: r031
  article-title: Dasatinib-induced colitis after allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
  publication-title: Biol Blood Marrow Transplant
– volume: 145
  start-page: 581
  year: 2009
  end-page: 597
  ident: r005
  article-title: Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
  publication-title: Br J Haematol
– volume: 1
  start-page: 250
  year: 2016
  end-page: 259
  ident: r015
  article-title: US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL.
  publication-title: Blood Adv
– volume: 88
  start-page: 275
  year: 2003
  end-page: 279
  ident: r021
  article-title: A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia.
  publication-title: Haematologica
– volume: 109
  start-page: 1408
  year: 2007
  end-page: 1413
  ident: r004
  article-title: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
  publication-title: Blood
– volume: 118
  start-page: 6521
  year: 2011
  end-page: 6528
  ident: r017
  article-title: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  publication-title: Blood
– volume: 123
  start-page: 843
  year: 2014
  end-page: 850
  ident: r011
  article-title: UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
  publication-title: Blood
– volume: 27
  start-page: 1081
  year: 2016
  end-page: 1088
  ident: r013
  article-title: Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
  publication-title: Ann Oncol
– volume: 101
  start-page: 1544
  year: 2016
  end-page: 1552
  ident: r018
  article-title: A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
  publication-title: Haematologica
– volume: 158
  start-page: 506
  year: 2012
  end-page: 514
  ident: r009
  article-title: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.
  publication-title: Br J Haematol
– volume: 124
  start-page: 2289
  year: 2014
  end-page: 2289
  ident: r032
  article-title: Phase II study of combination of hyper-CVAD with ponatinib in front line therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
  publication-title: Blood
– volume: 24
  start-page: 460
  year: 2006
  end-page: 466
  ident: r003
  article-title: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
  publication-title: J Clin Oncol
– volume: 128
  start-page: 774
  year: 2016
  end-page: 782
  ident: r014
  article-title: Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
  publication-title: Blood
– volume: 109
  start-page: 3676
  year: 2007
  end-page: 3678
  ident: r016
  article-title: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol.
  publication-title: Blood
– volume: 126
  start-page: 746
  year: 2015
  end-page: 756
  ident: r012
  article-title: Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: interim results of Korean Adult ALL Working Party Phase 2 Study.
  publication-title: Blood
– volume: 104
  start-page: 312
  year: 2019
  end-page: 318
  ident: r024
  article-title: Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
  publication-title: Haematologica
– volume: 16
  start-page: 1547
  year: 2015
  end-page: 1555
  ident: r033
  article-title: Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
  publication-title: Lancet Oncol
– ident: e_1_3_5_35_2
  doi: 10.1182/blood.V130.Suppl_1.99.99
– ident: e_1_3_5_23_2
  doi: 10.1038/sj.leu.2404586
– ident: e_1_3_5_36_2
  doi: 10.1182/blood-2017-07-796862
– ident: e_1_3_5_16_2
  doi: 10.1182/bloodadvances.2016001495
– ident: e_1_3_5_8_2
  doi: 10.1200/JCO.2010.28.1287
– ident: e_1_3_5_19_2
  doi: 10.3324/haematol.2016.144535
– ident: e_1_3_5_32_2
  doi: 10.1016/j.bbmt.2016.06.022
– ident: e_1_3_5_28_2
  doi: 10.1016/j.jbi.2008.08.010
– ident: e_1_3_5_17_2
  doi: 10.1182/blood-2006-10-052746
– ident: e_1_3_5_2_2
  doi: 10.1182/blood-2005-11-4386
– ident: e_1_3_5_6_2
  doi: 10.1111/j.1365-2141.2009.07666.x
– ident: e_1_3_5_31_2
  doi: 10.1038/leu.2016.174
– ident: e_1_3_5_9_2
  doi: 10.1182/blood-2009-12-261586
– ident: e_1_3_5_24_2
  doi: 10.1038/s41375-019-0413-0
– ident: e_1_3_5_20_2
  doi: 10.1182/blood.V126.23.81.81
– ident: e_1_3_5_29_2
  doi: 10.1016/j.jbi.2019.103208
– ident: e_1_3_5_14_2
  doi: 10.1093/annonc/mdw123
– ident: e_1_3_5_4_2
  doi: 10.1200/JCO.2005.03.2177
– ident: e_1_3_5_13_2
  doi: 10.1182/blood-2015-03-636548
– ident: e_1_3_5_25_2
  doi: 10.3324/haematol.2018.196055
– ident: e_1_3_5_15_2
  doi: 10.1182/blood-2016-02-700153
– ident: e_1_3_5_18_2
  doi: 10.1182/blood-2011-05-351403
– ident: e_1_3_5_12_2
  doi: 10.1182/blood-2013-09-529008
– ident: e_1_3_5_34_2
  doi: 10.1016/S1470-2045(15)00207-7
– ident: e_1_3_5_27_2
  doi: 10.1038/leu.2017.41
– volume: 88
  start-page: 275
  year: 2003
  ident: e_1_3_5_22_2
  article-title: A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia.
  publication-title: Haematologica
– ident: e_1_3_5_26_2
  doi: 10.1056/NEJMoa0808253
– ident: e_1_3_5_33_2
  doi: 10.1182/blood.V124.21.2289.2289
– ident: e_1_3_5_7_2
  doi: 10.3324/haematol.2009.011221
– ident: e_1_3_5_30_2
  doi: 10.3947/ic.2018.50.2.153
– ident: e_1_3_5_11_2
  doi: 10.1016/j.bbmt.2012.08.021
– ident: e_1_3_5_21_2
  doi: 10.1182/blood-2017-08-798322
– ident: e_1_3_5_3_2
  doi: 10.1038/sj.leu.2404320
– ident: e_1_3_5_5_2
  doi: 10.1182/blood-2006-03-011908
– ident: e_1_3_5_10_2
  doi: 10.1111/j.1365-2141.2012.09182.x
– reference: 33085866 - N Engl J Med. 2020 Oct 22;383(17):1673-1674
– reference: 33503351 - N Engl J Med. 2021 Jan 28;384(4):384
– reference: 33169006 - Nat Rev Clin Oncol. 2021 Jan;18(1):6
SSID ssj0000149
Score 2.7056127
Snippet In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of...
Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors....
BackgroundOutcomes in patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase...
SourceID proquest
pubmed
crossref
mms
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1613
SubjectTerms Acute lymphoblastic leukemia
Adult
Aged
Aged, 80 and over
Allografts
Antibodies, Bispecific - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone marrow
Cell death
Chemotherapy
Confidence intervals
Consolidation Chemotherapy
Dasatinib - administration & dosage
Design
Female
Gene expression
Glucocorticoids
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Hypotheses
Induction Chemotherapy
Induction therapy
Kinases
Leukemia
Lymphatic leukemia
Lymphocytes
Male
Medical prognosis
Middle Aged
Minimal residual disease
Monoclonal antibodies
Mutation
Pax5 protein
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Protein-tyrosine kinase
Proteins
Remission
Remission Induction
Survival Analysis
Targeted cancer therapy
Transplantation
Treatment Outcome
Title Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
URI https://nejm.org/doi/full/10.1056/NEJMoa2016272
https://www.ncbi.nlm.nih.gov/pubmed/33085860
https://www.proquest.com/docview/2453158639
https://www.proquest.com/docview/2453686409
Volume 383
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6xrYS4IMqrC-3KSIgTURM7fuSEtqVVhdqyQlTaW-TXiqUkabsJEjf-A_-QX8I4613oYTlnZEUez3yfPfZ8AK-plBxRI0-cdjzJlfaJMYonqUfyPAutrXstgvMLcXqZf5jyaTxwW8Rrlauc2Cdq19hwRn5Ac1wtXCGgvru-SYJqVKiuRgmNAWxnmINDYKqj7J_2UZH-xhOk2GMTMf8gKM03GtFPUEnvYNKgqhab6WYPOyeP4GHki2S8dPAO3PP1Y7h_HiviT-Djex3u49Rz8_vnr8PwurbtqqbShiAbJZMvyaS_lfXdk7HtWk_OfqD7GoOcGQckZ7678tVck3lNxqETx-IpXJ4cfz46TaJIQmJZkbZJwQskacYWNFW5Y4XmKbMss8YwnRmrPNNOWiuLzOvUcWl05iwTOrNCFjMt2TPYqpva7wKhM8tkXiDhC5skb7Xi0uX5zGnKDGdiCG9X01Ta2EE8CFl8K_tKNhflnVkdwpu1-fWydcYmwxHOeVn7r9Umg72VO8oYYovy74IYwqv1ZwyOUPHQtW-6pY1QAvewQ3i-dOP6VxhDtqlE-uL_g7-EBzRssRGuKN2Drfa28_vIQ1ozgoGcylG_5EawfXh8Mfn0B39-2oM
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB61RQIuiH8WSjEScMJqYsd2ckBoaam2dLf00Eq9pbbjFduSpLAJqDfegffgoXgSxvlZ6GG59ZyRFc189nzjGc8AvGBKCfQaEc10JmgUa0eNiQUNHJLnqW9t3cwimOzL0VH04Vgcr8Cv_i2ML6vsz8TmoM5K6-_IN1mEaBExOtS351-onxrls6v9CI0WFnvu4juGbPM3u9to35eM7bw_3BrRbqoAtRjfVzQRCbIaYxMWxFHGEy0CbnlojeE6NDZ2XGfKWpWETgeZUEaHmeVSh1aqZKoVx3VX4VrEufQlZPFW-E-7qo5udzdWXU9P5BibfrJ9qdHbSqbYJR-4mufz5fS2cXM7t-FWx0_JsAXUHVhxxV24Puky8Pfg47b29T_FzPz-8fOdf81b1XmZa0OQ_ZKDT_SgqQL75sjQ1pUj4wuES2mQo-OCZOzqM5fPNJkVZOg7f8zvw9GVqO8BrBVl4R4BYVPLVZQgwfRBmbM6FiqLommmGTeCywG87tWU2q5juR-c8TltMudCppe0OoBXC_HztlXHMsEN1HlauNN8mcB6b46029Lz9C8AB_B88Rk3o8-w6MKVdSsjY4kx8wAetmZc_ArnyG5jGTz-_-LP4MbocDJOx7v7e0_gJvPhPbpKxtZhrfpau6fIgSqz0QCPwMlVI_0P83QVzQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB61qVRxQfwTKMVIwAkr9q7Xax8qlJJGLU1DhKjUm9k_iwC2C7FBvfEOvBWPwZMw66wDPYRbzx6trNnZnW92Zr4BeEo4Z-g1Il8LzfwoEcaXMmF-YBA855baup1FcDKND0-j12fsbAN-db0wtqyyuxPbi1pXyr6RD0iE1sISdKiD3JVFzEbjl-dffDtBymZau3Eawo1Z0Hst3Zhr8jg2F98xnFvsHY1w758RMj549-rQdxMHfIWxf-2nLEXEI1VKgiTSNBUsoIqGSkoqQqkSQ4XmSvE0NCLQjEsRakVjEaqYp7ngFNfdhC2OXpL0YGv_YDp7-w-ZlQPj7j3LMX4iAhnYufeVQF8cE04uecjNolisB7-tExzfgOsOvXrDpbndhA1T3oLtE5efvw1vRsJWB5Vz-fvHz33b61s3RVUI6SE29mYf_FlbI_bNeEPV1MabXKAxVRIRPC7oTUzzyRRz4c1Lb2h5QRZ34PRKFHgXemVVmvvgkVxRHqUIP23IZpRIGNdRlGtBqGQ07sOLTk2ZcnzmdqzG56zNq7M4u6TVPjxfiZ8viTzWCe6izrPSfCzWCex025G5A7_I_ppnH56sPuNRtfkXUZqqWcrESYwRdR_uLbdx9SuUIvZN4uDB_xd_DNto9dnkaHr8EK4RG_ujHyVkB3r118Y8QoBUy11neR68v2pj_wMQgSDE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dasatinib%E2%80%93Blinatumomab+for+Ph-Positive+Acute+Lymphoblastic+Leukemia+in+Adults&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Fo%C3%A0%2C+Robin&rft.au=Bassan%2C+Renato&rft.au=Vitale%2C+Antonella&rft.au=Elia%2C+Loredana&rft.date=2020-10-22&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=383&rft.issue=17&rft.spage=1613&rft.epage=1623&rft_id=info:doi/10.1056%2FNEJMoa2016272&rft.externalDBID=n%2Fa&rft.externalDocID=10_1056_NEJMoa2016272
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon